Clinical Validation of a New Algorithm for Computerized Dosing of Vitamin K Antagonist Therapy
NCT01392040 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2013-01-17
Summary
The purpose of this study is to determine whether the new algorithm is safety and effective in proposing the dosage and the timing of oral anticoagulant therapy.
Conditions
- Anticoagulated Patients
Sponsors & Collaborators
-
University Of Perugia
lead OTHER
Principal Investigators
-
Michela Basileo, Dr · University Of Perugia
-
Alfonso Iorio, Dr · McMaster University
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-11-30
- Primary Completion
- 2012-08-31
- Completion
- 2013-01-31
Countries
- Italy
Study Locations
More Related Trials
-
Excessive Warfarin Anticoagulation - Causes and Consequences
NCT02761941 ·Status: UNKNOWN
-
Safety Study of Vitamin K2 During Anticoagulation in Human Volunteers
NCT00512928 ·Status: COMPLETED ·Phase: NA
-
Dose-Response in PD and Safety of Cofact Under VKA Anticoagulation
NCT05205863 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis
NCT04660747 ·Status: RECRUITING
-
Daily Vitamin K in Patients on Warfarin With Unstable INRs
NCT00287313 ·Status: COMPLETED ·Phase: NA
-
Comparative Study Between Thrombosis Prophylaxis Protocols
NCT00713973 ·Status: COMPLETED
-
Patient Convenience Study
NCT02597920 ·Status: COMPLETED
-
Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study
NCT03292666 ·Status: COMPLETED
-
Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
NCT04066764 ·Status: RECRUITING ·Phase: PHASE3
-
Balancing of Patients Treated by Vitamin K Antagonists (VKAS) in General Medicine
NCT03914053 ·Status: COMPLETED
-
An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding
NCT02319460 ·Status: COMPLETED
-
Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters
NCT00024297 ·Status: COMPLETED ·Phase: NA
-
Prevention of Cefoperazone-induced Coagulopathy
NCT05742295 ·Status: COMPLETED ·Phase: PHASE4
-
Optimal Duration of Anticoagulation in Deep Venous Thrombosis
NCT01285661 ·Status: COMPLETED ·Phase: PHASE3
-
Educ'Avk: Recommendations for the Antivitamin K's Gestion
NCT00227097 ·Status: TERMINATED
-
Improving Anticoagulant Therapy Through Warfarin Metabolite Profiling
NCT01964794 ·Status: COMPLETED
-
Early Identification of Warfarin Maintenance Dosage
NCT01178034 ·Status: COMPLETED ·Phase: PHASE3
-
Prevention of Thrombosis Recurrence in Patients With Low Circulating Levels of Antithrombin.
NCT01382550 ·Status: UNKNOWN
-
Oral Vitamin K for Warfarin Associated Coagulopathy
NCT00143715 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal
NCT01159210 ·Status: COMPLETED ·Phase: PHASE4
-
Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists
NCT01722786 ·Status: COMPLETED
-
Validation of International Warfarin Pharmacogenetics Consortium (IWPC) Algorithm in Elderly Patients With Comorbidity
NCT02069132 ·Status: UNKNOWN
-
Prevention and Prophylaxis of Cancer Associated Thrombosis in High Risk Oncology Patients
NCT03909399 ·Status: UNKNOWN
-
Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients
NCT02592980 ·Status: UNKNOWN ·Phase: PHASE4
-
Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over
NCT02286414 ·Status: COMPLETED